Medindia

X

Signalife Wins Second Frost & Sullivan Technology Award

Friday, March 14, 2008 General News J E 4
Advertisement
LOS ANGELES, March 13 Signalife, Inc.(Amex: SGN) has received its second Frost & Sullivan Technology Award in thepast three years. On March 12, 2008, at the Frost & Sullivan Awards Banquet,Signalife was awarded the Frost & Sullivan Technology Innovation Award forNorth American Patient Monitoring. Signalife's Chief Executive Officer, Dr.Lowell Harmison, and its inventor and Chief Scientist, Dr. Budimir Drakulic,were present to accept the award.

Signalife, Inc. is in a rare and prestigious group of companies, as adevice-maker that has won the award from Frost & Sullivan two times in thepast three years.

In the words of Frost & Sullivan, the Technology Award "is presented toSignalife in recognition of its superior leadership and vision in patientmonitoring with its Fidelity heart monitoring systems. Signalife's uniquetechnology provides unprecedented signal clarity in the highly sought-afterreal-time, wireless cardiac monitoring arena."

Frost & Sullivan continues: "Signalife strived to provide one of the mosttrustworthy and reliable wireless monitoring product out there, and theyaccomplished this by creating a technology that significantly reduced andeffectively eliminated artifact noise before the ECG signal is amplified.This results in no need to filter the signal after it has been amplifiedpreserving the entire ECG's data. Using this as the basis of all theirtechnology, Signalife has been able to set themselves apart from other cardiacmonitors. The Fidelity 100 is the first of their products, and is comprisedof a wireless, real-time 12 lead ECG system ... "

Frost & Sullivan concludes: "While the Fidelity 100 product alone makes acase for product innovation, what really puts Signalife over the top is itsother two products at end stage development, [including the Fidelity 200,which] is taking cardiac event monitoring to a place the industry has neverbeen before, the over the counter, non-prescription market. As cardiacconditions continue to be the number one killer in the US, real self cardiacmonitoring continues to be out of the reach of the health conscious consumer.This product works to alleviate that, by providing a credit card sized fullyfunctional medical grade event monitor ... "

Frost & Sullivan choose Signalife -- from all others in heart monitoring -- through careful analysis that included interviews with major marketparticipants and extensive secondary research. In accordance with Frost &Sullivan's strict policy of independence, the Company was not contacted priorto receiving notification that it was the recipient of the award.

Dr. Lowell T. Harmison -- Signalife's President and Chief ExecutiveOfficer -- commented: "I would like to personally thank Dr. Budimir Drakulic-- who I believe to be one of the most brilliant micro-electronics experts inthe world -- as well as his team. It is not promotional to say that Signalifeis now "over the top" in terms of giving this industry the means to change itscore technology to obtain more accurate ECG's for better heart monitoring. Asa result, it should alter the way heart disease is monitored, diagnosed andtreated in general. Indeed, "over the top" are not my words -- they are Frost& Sullivan's. I personally look forward to unveiling a series of corporateevents that will guide the profession to these solutions. Stay tuned."

Signalife will make the full Frost & Sullivan analyst report -- as well asother events surrounding the receipt of this prestigious award -- available tothe public in the upcoming two weeks.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring,detection and prevention of disease through continuous biomedical signalmonitoring. Signalife uses its patented signal technology to design anddevelop medical devices, therapies and/or technologies that simplify andreduce the costs of cardiova
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
The Endovascular Forum Announces Partnerships with...
S
Payformance Completes Sale of Corporate Payments D...